EMOTIONS

从基本的情感研究中衍生出来的基于推理的方法可以提供一个细粒度的，在体内的 额颞叶变性和阿尔茨海默病患者情绪功能的评估 (AD)两种最常见的精神错乱在下一个项目期间，我们将继续和扩大 这种转化研究策略，使用这些方法来检查多种情绪过程（反应， 调节、知识、社会情绪行为），多种情绪反应系统（外周生理学， 表达行为，主观体验，眼球运动，语言），多种情绪家族（积极， 消极的，自我意识的情绪），和多种情绪背景（自我和人际）在FTLD 患者、AD患者和年龄匹配的正常对照。与本次更新的其他项目一样，我们将 增加我们的重点：（a）区分额颞叶痴呆（FTD）的FTLD亚型， 进行性非流利性失语（PNFA）和语义性痴呆（SD）;（B）将情绪功能映射到 在指定的大脑区域的体积损失和灌注不足，以及（c）探索情绪功能， 肌萎缩侧索硬化症（ALS）患者。本研究提出了六个具体目标：（1）使用 从基础情绪研究中获得的方法来评估情绪功能（反应性，调节， （2）通过研究FTLD和AD患者的社会行为， 与照顾者的互动;（3）评估脑容量损失的特定区域与 灌注不足和伴随的情感功能和社会行为的缺陷;（4） 描述FTLD亚型（FTD，PNFA，SD）之间以及这些亚型之间的情绪功能差异 亚型和ALS;（5）评估低水平情绪过程的完整性（惊吓眨眼调制 通过情绪，眼动捕捉和搜索模式的情绪刺激，前注意的处理， 情绪信息）;（6）确定神经心理和 认知功能的床边测量和情绪功能的实验室评估。这 研究对公共卫生有重大益处。我们相信这些发现将被证明是非常有用的， 提高临床诊断的准确性，监测疾病进展的过程，了解 的基础，评估目前和未来治疗的有效性，并在帮助 提高患者及其家属的生活质量。

Laboratory-based methods derived from basic emotion research can provide a fine-grained, in vivo assessment of emotional functioning in frontotemporal lobar degeneration (FTLD) and Alzheimer's disease (AD) two of the most common dementing disorders. In the next project period, we will continue and expand this translational research strategy, using these methods to examine multiple emotion processes (reactivity, regulation, knowledge, socioemotional behavior), multiple emotion response systems (peripheral physiology, expressive behavior, subjective experience, eye movements, language), multiple emotion families (positive, negative, self-conscious emotions), and multiple emotion contexts (intrapersonal and interpersonal) in FTLD patients, AD patients, and age-matched normal controls. As with the other projects in this renewal, we will increase our emphasis on: (a) distinguishing between FTLD subtypes of frontotemporal dementia (FTD), progressive non-fluent aphasia (PNFA), and semantic dementia (SD); (b) mapping emotional functioning on to volume loss and hypoperfusion in designated brain regions, and (c) exploring emotional functioning in patients with amyotrophic lateral sclerosis (ALS). The research addresses six specific aims: (1) to use methods derived from basic emotion research to evaluate emotional functioning (reactivity, regulation, knowledge) in FTLD and AD; (2) to evaluate social behavior in FTLD and AD patients by studying dyadic interaction with caregivers; (3) to evaluate relationships between specific regions of brain volume loss and hypoperfusion and attendant deficits in and preservation of emotional functioning and social behavior; (4) to delineate differences in emotional functioning among FTLD subtypes (FTD, PNFA, SD) and between these subtypes and ALS; (5) to evaluate the integrity of low-level emotional processes (startle eye-blink modulation by emotion, eye-movement capture by and search patterns for emotional stimuli, preattentive processing of emotional information) in FTLD and AD; and (6) to determine the relations between neuropsychological and bedside measures of cognitive functioning and laboratory-based assessment of emotional functioning. This research has significant public health benefits. We believe the findings will prove to be extremely useful in improving the accuracy of clinical diagnosis, monitoring the course of disease progression, understanding the basis of symptomatology, evaluating the effectiveness of present and future treatments, and in helping improve quality of life for patients and their families.